Press Room
四色AV and Ripple Enter Strategic Partnership to Expand Epidel庐 Platform into Non-Ophthalmic Space
四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple's Epidel庐 platform beyond ophthalmic applications.
Lisbon, March 20, 2023, 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel庐 platform beyond ophthalmic applications.听
听
The core feature of Ripple鈥檚 Epidel庐 technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel庐 platform into its toolbox, 四色AV can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.
听
鈥淭he combination of technology synergy, innovative vision and cultural fit makes collaborating with 四色AV an exciting next step in the advancement of the Epidel庐 platform beyond the ophthalmic field,鈥 stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. 鈥溗纳獳V鈥檚 expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.鈥
听
"We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, 四色AV's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide."
By extending the use of the Epidel庐 platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles.听
听
鈥嬧赌嬧赌嬧赌嬧赌About 四色AV
四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a听Contract Development and Manufacturing Organization (CDMO)听with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected听sites听in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the听development and compliant manufacture听of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
听
About Ripple Therapeutics
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple鈥檚 Epidel鈩 technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple鈥檚 novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development.
听
听
